Tag: precision oncology
Cipla Partners with SBP Group for Next-Gen HER2 Cancer Therapy
Cipla Limited and Sino Biopharmaceutical Limited (SBP Group) announced that SBP Group's subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), has entered into an exclusive license...
AstraZeneca Licenses Novel Lung Cancer Drug Zegfrovy in $1.5B Global Deal
AstraZeneca announced a exclusive global license agreement with Dizal Pharmaceutical to develop and commercialize Zegfrovy (sunvozertinib), a highly differentiated, oral irreversible EGFR inhibitor designed for targeted lung cancer...
GSK Launches Tender Offer to Acquire Precision Oncology Innovator Nuvalent, Inc.at $124.00
GSK plc has officially commenced a tender offer to acquire all issued and outstanding shares of Class A and Class B common stock of Nuvalent,...
Novartis strikes a $1.9B partnership with Antares Therapeutics to tackle “undruggable” cancer targets.
Novartis has entered into a strategic collaboration and license agreement with Antares Therapeutics to discover and develop next-generation small molecule oncology treatments. The transaction...
Johnson & Johnson to acquire Firefly Bio to advance novel cancer treatment
Johnson & Johnson announced that it has entered into a definitive agreement to acquire Firefly Bio, Inc., a privately held biotechnology company specializing in...
